Clayton Blehm, MD
Ophthalmology · Gainesville, GANPI 1235127713
Payments from drug & device makers
Across 294 payments — averaging $5830.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$1.7M
- Topcon Healthcare, Inc.$19K
- Alcon$18K
- Sun Pharmaceutical Industries Inc.$4K
- Bausch & Lomb Americas Inc.$4K
- AbbVie$693
- plus $3K from 22 others
Across 10 payments — averaging $44,150 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$442K
What the payments were for
- Consulting fees$25,83662%
- Speaking & faculty fees$3,97610%
- Travel & lodging$2,2745%
- Food & beverage$9,18322%
- Education$2471%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 40 | $1,666,791 |
| Topcon Healthcare, Inc. | 2 | $18,725 |
| Alcon | 117 | $18,265 |
| Sun Pharmaceutical Industries Inc. | 37 | $3,619 |
| Bausch & Lomb Americas Inc. | 7 | $3,538 |
| AbbVie(2 entities) | 36 | $693 |
| Rxsight Inc | 6 | $571 |
| Ocular Therapeutix, Inc. | 5 | $295 |
| Dompe US, Inc. | 5 | $282 |
| Novartis | 5 | $208 |
| Eyevance Pharmaceuticals LLC | 2 | $182 |
| Lensar, Inc. | 2 | $168 |
| Tarsus Pharmaceuticals, Inc. | 3 | $130 |
| Mallinckrodt Hospital Products Inc. | 3 | $129 |
| NEW World Medical,inc. | 2 | $113 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $81 |
| Astellas Pharma US Inc | 1 | $75 |
| Glaukos Corporation | 2 | $71 |
| Biotissue Holdings Inc. | 3 | $52 |
| Rayner Intraocular Lenses Limited | 2 | $52 |
| Aerie Pharmaceuticals, Inc. | 3 | $51 |
| Kala Pharmaceuticals, Inc. | 3 | $50 |
| Shire North American Group Inc | 2 | $24 |
| Omeros Corporation | 1 | $20 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $18 |
| Oyster Point Pharma, Inc. | 1 | $16 |
| Carl Zeiss Meditec USA, Inc. | 1 | $13 |
| Sight Sciences, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$23,210
- AcrySof IQ VIVITY$9,606
- AcrySof IQ PanOptix UV IOL$9,090
- CEQUA$2,427
- DEXTENZA$600
- RXSIGHT CONTACT LENS$530
- RXSIGHT INJECTOR HANDPIECE$530
- RXSIGHT INJECTOR CARTRIDGE$530
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$530
- LIGHT ADJUSTABLE LENS (LAL)$287
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$243
- ReSTOR$231
- BROMSITE$228
- ORA$226
- LenSx$217
- AcrySof IQ PanOptix$186
- Flarex$165
- LENSAR LASER SYSTEM$150
- AcrySof IQ VIVITY IOL$141
- NGENUITY$110
How this compares
$1,714,244 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 24 | $36,463 |
| LumiganBimatoprost | 43 | $28,418 |
| XiidraLifitegrast | 12 | $17,699 |
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $12,812 |
| Latanoprost | 688 | $10,275 |
| Travoprost | 45 | $9,519 |
| Cyclosporine | 15 | $7,955 |
| Brimonidine Tartrate | 119 | $4,922 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $4,512 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $4,293 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $4,266 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 173 | $3,375 |
| Timolol Maleate | 182 | $2,121 |
| Dorzolamide Hcl | 101 | $1,657 |
| Prednisolone Acetate | 42 | $1,564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $693 | $69,14779 claims |
| Bausch & Lomb Americas Inc.Xiidra | $3,538 | $17,69912 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $51 | $12,81230 claims |
| AlconSimbrinza | $18,265 | $4,29321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Gainesville
- Jack ChapmanGainesville$305K
- Zachary BalestGainesville$50K
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.